의약품 정밀 화학(Fine Chemicals) 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 제품별, 화학물질별, 용도별, 지역별 및 부문별 예측(2023-2030년)

Pharmaceutical Fine Chemicals Market Growth & Trends:

The global pharmaceutical fine chemicals market is expected to reach USD 233.5 billion by 2030, according to a new report by Grand View Research, Inc.. It is expected to expand at a CAGR of 7.9% from 2023 to 2030. Increasing demand for preventive healthcare is expected to be a major factor in driving the market growth. The utilization of pharmaceutical fine chemicals (PFCs) has increased on account of the increasing aging population across the globe.

Cardiovascular is anticipated to the fastest-growing application segment over the next eight years growing at an estimated CAGR of 8.4%. The occurrence of cardiovascular disease is on the rise owing to the unhealthy lifestyle of human beings. According to the World Health Organization (WHO), cardiovascular diseases are considered to be the prime cause of fatalities across the globe. The organization also states that cardiovascular diseases caused the death of approximately 17.7 million people in the year 2015. This number approximately represented 31% of the total deaths in the year 2015.

Obesity and an unhealthy lifestyle are some of the most important factors which lead to the occurrence of various diseases such as cardiovascular, neurological, oncological, infectious diseases, metabolic system, diabetes, respiratory, gastrointestinal, and musculoskeletal disorders. Eating junk food, leading unhygienic lifestyle, irregular timetable and many other unhealthy habits lead to diseases amongst human beings. Studies also show that males have more chance of contracting diabetes as compared to females. All these factors combined are thus anticipated to propel the market growth over the forecast period.

Pharmaceutical Fine Chemicals Market Report Highlights:

• Proprietary emerged as the largest type segment in 2022 and is estimated to generate revenue share of 81.6% in 2022
• Big molecules were the largest size segment in 2022 and are expected to grow at an estimated CAGR of 7.8% over the next eight years
• The basic building blocks segment is expected to register a CAGR of 7.5% over the forecast period. Basic building blocks is a virtual molecular fragment possessing a reactive functional group
• North America dominated the global pharmaceutical fine chemicals market and accounted for the largest revenue share of 37.3% in 2022. North America region is characterized by the presence of strict laws and regulations about manufacturing as well as consumption.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Type
  • 1.1.2. Product
  • 1.1.3. Chemical
  • 1.1.4. Application
  • 1.1.5. Regional scope
  • 1.1.6. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
• 1.5. Market Formulation & Validation
• 1.6. Model Details
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Product outlook
  • 2.2.3. Chemical outlook
  • 2.2.4. Application outlook
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Pharmaceutical Fine Chemicals Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
• 3.5. Market Dynamics
  • 3.5.1. Market Driver Analysis
  • 3.5.2. Market Restraint Analysis
  • 3.5.3. Industry opportunities & challenges
• 3.6. Pharmaceutical Fine Chemicals Market Analysis Tools
  • 3.6.1. Industry Analysis - Porter's
    • 3.6.1.1. Supplier power
    • 3.6.1.2. Buyer power
    • 3.6.1.3. Substitution threat
    • 3.6.1.4. Threat of new entrant
    • 3.6.1.5. Competitive rivalry
  • 3.6.2. PESTEL analysis
    • 3.6.2.1. Political landscape
    • 3.6.2.2. Technological landscape
    • 3.6.2.3. Economic landscape
    • 3.6.2.4. Social landscape
    • 3.6.2.5. Environmental landscape
    • 3.6.2.6. Legal landscape

Chapter 4. Supplier Portfolio Analysis

• 4.1. List of Suppliers
• 4.2. Kraljic Matrix
• 4.3. Sourcing Best Practices
• 4.4. Negotiation Strategies

Chapter 5. Pharmaceutical Fine Chemicals: Type Estimates & Trend Analysis

• 5.1. Pharmaceutical Fine Chemicals Market: Key Takeaways
• 5.2. Pharmaceutical Fine Chemicals Market: Movement & Market Share Analysis, 2022 & 2030
• 5.3. Proprietary
  • 5.3.1. Proprietary market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.4. Non-Proprietary
  • 5.4.1. Non Proprietary market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Pharmaceutical Fine Chemicals: Product Estimates & Trend Analysis

• 6.1. Pharmaceutical Fine Chemicals Market: Key Takeaways
• 6.2. Pharmaceutical Fine Chemicals Market: Movement & Market Share Analysis, 2022 & 2030
• 6.3. Basic Building Blocks
  • 6.3.1. Basic building blocks market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.4. Advanced Intermediates
  • 6.4.1. Advanced intermediates market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.5. Active Ingredients
  • 6.5.1. Active ingredients market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Pharmaceutical Fine Chemicals: Chemical Estimates & Trend Analysis

• 7.1. Pharmaceutical Fine Chemicals Market: Key Takeaways
• 7.2. Pharmaceutical Fine Chemicals Market: Movement & Market Share Analysis, 2022 & 2030
• 7.3. Small Molecules
  • 7.3.1. Small molecules market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.4. Big Molecules
  • 7.4.1. Big molecules market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Pharmaceutical Fine Chemicals: Application Estimates & Trend Analysis

• 8.1. Pharmaceutical Fine Chemicals Market: Key Takeaways
• 8.2. Pharmaceutical Fine Chemicals Market: Movement & Market Share Analysis, 2022 & 2030
• 8.3. Cardiovascular
  • 8.3.1. Cardiovascular market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.4. Neurological
  • 8.4.1. Neurological market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.5. Oncological
  • 8.5.1. Oncological market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.6. Infectious Diseases
  • 8.6.1. Infectious diseases market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.7. Metabolic System
  • 8.7.1. Metabolic system market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.8. Diabetes
  • 8.8.1. Diabetes market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.9. Respiratory
  • 8.9.1. Respiratory market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.10. Gastrointestinal
  • 8.10.1. Gastrointestinal market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.11. Musculoskeletal
  • 8.11.1. Musculoskeletal market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.12. Others
  • 8.12.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 9. Pharmaceutical Fine Chemicals Market: Regional Estimates & Trend Analysis

• 9.1. Regional Outlook
• 9.2. Pharmaceutical Fine Chemicals Market by Region: Key Takeaway
• 9.3. North America
  • 9.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 9.3.2. U.S.
    • 9.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 9.3.3. Canada
    • 9.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 9.3.4. Mexico
    • 9.3.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 9.4. Europe
  • 9.4.1. UK
    • 9.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 9.4.2. Germany
    • 9.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 9.4.3. France
    • 9.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 9.4.4. Italy
    • 9.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 9.4.5. Spain
    • 9.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 9.5. Asia Pacific
  • 9.5.1. Japan
    • 9.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 9.5.2. China
    • 9.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 9.5.3. India
    • 9.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 9.5.4. South Korea
    • 9.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 9.6. Central & South America
  • 9.6.1. Brazil
    • 9.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 9.6.2. Argentina
    • 9.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 9.7. MEA
  • 9.7.1. Saudi Arabia
    • 9.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 9.7.2. South Africa
    • 9.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis, By Key Market Participants
• 10.2. Market Participant Categorization
  • 10.2.1. Denisco
    • 10.2.1.1. Company overview
    • 10.2.1.2. Financial performance
    • 10.2.1.3. Product benchmarking
    • 10.2.1.4. Strategic initiatives
  • 10.2.2. Albemarle Corporation
    • 10.2.2.1. Company overview
    • 10.2.2.2. Financial performance
    • 10.2.2.3. Product benchmarking
    • 10.2.2.4. Strategic initiatives
  • 10.2.3. Kenko Corporation
    • 10.2.3.1. Company overview
    • 10.2.3.2. Financial performance
    • 10.2.3.3. Product benchmarking
    • 10.2.3.4. Strategic initiatives
  • 10.2.4. GRACE
    • 10.2.4.1. Company overview
    • 10.2.4.2. Financial performance
    • 10.2.4.3. Product benchmarking
    • 10.2.4.4. Strategic initiatives
  • 10.2.5. CHEMADA
    • 10.2.5.1. Company overview
    • 10.2.5.2. Financial performance
    • 10.2.5.3. Product benchmarking
    • 10.2.5.4. Strategic initiatives
  • 10.2.6. JMP Statistical Discovery LLC.
    • 10.2.6.1. Company overview
    • 10.2.6.2. Financial performance
    • 10.2.6.3. Product benchmarking
    • 10.2.6.4. Strategic initiatives
  • 10.2.7. Pfizer Inc.
    • 10.2.7.1. Company overview
    • 10.2.7.2. Financial performance
    • 10.2.7.3. Product benchmarking
    • 10.2.7.4. Strategic initiatives
  • 10.2.8. GSK plc
    • 10.2.8.1. Company overview
    • 10.2.8.2. Financial performance
    • 10.2.8.3. Product benchmarking
    • 10.2.8.4. Strategic initiatives